Using stem cells to treat end-stage liver disease
Efficacy and Safety of Different Frequencies of Human Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients with End-stage Liver Disease
NA · General Hospital of Shenyang Military Region · NCT06242405
This study is testing if giving people with end-stage liver disease one or two infusions of stem cells can improve their liver function.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 92 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | General Hospital of Shenyang Military Region (other) |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT06242405 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of different frequencies of umbilical cord-mesenchymal stem cell infusions in patients with end-stage liver disease (ESLD). Ninety-two participants will be randomly assigned to receive either a single or double infusion of stem cells through a peripheral vein. The study aims to evaluate various liver function parameters, including liver enzymes and scores related to liver disease, at 24 weeks post-infusion. The goal is to determine whether multiple infusions provide better outcomes than a single infusion.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-80 diagnosed with end-stage liver disease who can provide informed consent.
Not a fit: Patients with liver tumors, those who have undergone liver transplantation, or individuals with severe cardiopulmonary diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve liver function and quality of life for patients with end-stage liver disease.
How similar studies have performed: Previous studies have shown promising results with stem cell infusions for liver conditions, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1. 18-80 years old * 2. End-stage liver disease * 3. Signed informed consent Exclusion Criteria: * 1. Tumours of the liver or other organs * 2. Liver transplantation recipients * 3. Acute myocardial infarction, acute heart failure, type I and type II respiratory failure, pulmonary embolism, acute cerebral infarction, acute cerebral haemorrhage and other serious cardiopulmonary diseases * 4. Other diseases that may seriously affect the survival * 5. Human immunodeficiency syndrome * 6. Interferon or glucocorticoid therapy within 1 year * 7. Treated for mental illness * 8. Participation in other clinical trials within 30 days * 9. Pregnant or breastfeeding subjects * 10. Allergic asthma, allergic urticaria, eczema, or a history of multiple drug and food allergies * 11. Other circumstances that are unsuitable for participation in this study
Where this trial is running
Shenyang, Liaoning
- General Hospital of Northern Theater Command — Shenyang, Liaoning, China (RECRUITING)
Study contacts
- Principal investigator: Wen Ning, MM — The General Hospital of Northern Theater Command
- Study coordinator: Xingshun Qi, MD
- Email: xingshunqi@126.com
- Phone: 18909881019
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: End-Stage Liver DIsease, cirrhosis, end-stage liver diseases, umbilical cord-mesenchymal stem cells, randomized controlled trial